Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy.
To report long-term functional and anatomic results of safety-enhanced photodynamic therapy (PDT) with half-dose verteporfin for chronic central serous chorioretinopathy (CSC). A retrospective analysis of 29 eyes of 27 patients with chronic CSC was performed. All eyes received half-dose PDT. Visual acuity, central foveal thickness, and angiographic features were evaluated. Mean follow-up time was 20 months (range 12-40). Mean best-corrected visual acuity improved from 0.45 ± 0.23 logMAR to 0.08 ± 0.08 logMAR. Twenty-five eyes (86%) had a complete resolution of the subretinal fluid after only one session and 4 eyes had recurrences, 3 of them at the same leaking area observed at baseline. At the end of the follow-up all eyes (100%) showed resolution of the subretinal fluid. There was no visual loss secondary to exaggerated response to the PDT, nor any other adverse events. The long-term results of this study further support the safety and effectiveness of safety-enhanced PDT with half dose of verteporfin for the treatment of chronic CSC.